Get the Daily Brief
Latest Biotech News
Novartis Licenses Argo Biopharma’s Cardiovascular siRNA Assets in $160 Million Deal
Novartis expanded its RNA therapeutics pipeline with a multi-asset licensing agreement worth up to $5.2 billion with Argo Biopharma, focusing on small interfering RNA candidates targeting...
Charm Therapeutics Raises $80 Million to Advance Next-Generation Menin Inhibitor in Leukemia
London-based Charm Therapeutics secured $80 million in a Series B funding round co-led by New Enterprise Associates and DR One to support clinical development of its menin inhibitor targeting...
MD Anderson Cancer Center Reports Recent Breakthroughs Across Multiple Tumor Types
The University of Texas MD Anderson Cancer Center announced innovative advances in oncology research encompassing pancreatic, colorectal, kidney, breast, stomach, and testicular cancers. Employing...
FDA Enhances Transparency with Real-Time Drug Rejection Letter Releases
The U.S. Food and Drug Administration (FDA), under Commissioner Marty Makary, has initiated a significant policy shift to release complete response letters (CRLs) publicly in real time, concurrent...
Atlas Venture Raises $400 Million to Bolster Biotech Portfolio
Atlas Venture, a prominent Boston-based biotech venture capital firm, has closed a $400 million Opportunity Fund designed to support its existing portfolio of drug development startups. This...
Breakthrough CAR T-Cell Therapy in Multiple Sclerosis Marks Clinical Milestone
The University of Nebraska’s Fred & Pamela Buffett Cancer Center has pioneered the first treatment of a multiple sclerosis (MS) patient using an allogeneic chimeric antigen receptor (CAR) T-cell...
BioNTech and Duality Biologics Report Phase III Breast Cancer ADC Success
BioNTech SE and its partner Duality Biologics announced a successful interim analysis from their Phase III trial involving trastuzumab pamirtecan, an HER2-targeting antibody-drug conjugate (ADC),...
Immunovant and Roivant Unveil Positive Phase II Data in Autoimmune Graves’ Disease
Immunovant Inc., a Roivant Sciences subsidiary, disclosed encouraging six-month off-treatment outcomes from a single-arm Phase II study of batoclimab in patients with uncontrolled Graves’ disease....
Enveda Biosciences Raises $150 Million to Advance Drug Discovery Pipeline
Enveda Biosciences, a Colorado-based biotechnology firm specializing in harnessing natural products and artificial intelligence for drug discovery in inflammation and immunology, has secured $150...
Spaceflight Accelerates Aging in Human Stem Cells, UC San Diego Finds
A novel study led by researchers at the University of California San Diego’s Sanford Stem Cell Institute reveals that human hematopoietic stem and progenitor cells (HSPCs) experience accelerated...
Scripps Research Identifies Human Proteins Critical for SARS-CoV-2 Replication
Scientists at Scripps Research conducted a comprehensive siRNA screen that pinpointed key human host proteins exploited by SARS-CoV-2 during various infection stages. The study revealed 59...
Novartis Deepens Collaboration With Argo Biopharma on Cardiovascular RNA Therapies
Novartis has expanded its partnership with Argo Biopharma through a multi-asset licensing and options deal valued up to $5.2 billion, focusing on small interfering RNA (siRNA) candidates targeting...
Atlas Venture Raises $400 Million to Support Portfolio Biotechs
Atlas Venture, a key player in biotech venture capital, announced the closing of a $400 million Opportunity Fund aimed at backing existing portfolio companies. This third fund follows a $450...
FDA Enhances Transparency with Real-Time Release of Drug Rejection Letters
The U.S. Food and Drug Administration (FDA) has committed to unprecedented transparency by pledging to publish complete response letters (CRLs) to drug developers at the time they are issued. This...
BioNTech and Duality Biologics' HER2 Antibody-Drug Conjugate Surpasses Roche in Phase 3 Breast Cancer Trial
In a significant oncology breakthrough, BioNTech and its partner Duality Biologics demonstrated that their HER2-targeting antibody-drug conjugate (ADC), trastuzumab pamirtecan, surpassed Roche’s...
Radiance Biopharma Secures $1.165 Billion Deal for Bispecific Nanobody ADC Targeting Solid Tumors
Late-stage oncology capacity expansion is underscored by Radiance Biopharma’s signing of a multi-billion-dollar licensing agreement with China-based Novatim Immune Therapeutics. The pact grants...
Sanofi’s Amlitelimab Achieves Phase III Endpoints in Atopic Dermatitis but Fails to Meet Expectations
Sanofi announced that its atopic dermatitis candidate, amlitelimab, met primary endpoints in a phase III clinical trial; however, the data fell short of industry and investor expectations relative...
Charm Therapeutics Raises $80 Million to Advance Next-Generation Menin Inhibitor for Leukemia
Charm Therapeutics secured $80 million in Series B funding led by New Enterprise Associates and DR One to propel clinical development of its menin inhibitor aimed at treating acute myeloid...
University of California San Diego Finds Spaceflight Accelerates Aging of Human Stem Cells
A study led by UC San Diego's Sanford Stem Cell Institute reveals that human hematopoietic stem and progenitor cells (HSPCs) undergo accelerated aging during spaceflight. Using AI-enabled...
Scripps Research Identifies Human Host Proteins Critical for SARS-CoV-2 Replication, Revealing New Therapeutic Targets
Scripps Research scientists conducted a comprehensive siRNA screen to pinpoint host proteins indispensable to SARS-CoV-2 infection, identifying 32 proteins critical in early viral entry and 27...